Liposomal bupivacaine

布比卡因脂质体

Report date: 2026/05/15 20:01:45

Base Information

Drug NameLiposomal bupivacaine
Drug Alias NameDepobupivacaineLiposomal bupivacainebupivacaineBupivacaine liposome injectable suspensionBupivacaine liposome extended-release injectable suspension +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockers
TargetsSodium channel alpha subunit
Therapy Area/IndicationsShoulder FracturesRib FracturesWounds and Injuries +[34] 
Global Approved IndicationsPainPain, Postoperative
Approved Indications in ChinaPain
Original Approved Country/TerritoryUnited States
Original Approved Date2011/10/28
Country/TerritoryUnited StatesEUHong Kong +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPacira Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesPacira Ireland LtdNuance Biotech Co LtdWake Forest University Health Sciences +[12] 
Inactive CompaniesUniversity Of California San FranciscoUniversity of Texas Southwestern Medical CenterGeorgetown University +[8] 
Active IndicationsOpioid-Related DisordersBack PainPain +[18] 
Inactive IndicationsShoulder FracturesRib FracturesWounds and Injuries +[16] 

Other Information

ATC CodeN01BB01
Related LinksWikipediaDrugBankKEGG